A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 58
Summary
- Conditions
- Adenocarcinoma
- Digestive System Disease
- Digestive System Neoplasm
- Endocrine Gland Neoplasms
- Endocrine System Diseases
- Neoplasm, Glandular
- Neoplasms
- Neoplasms Pancreatic
- Pancreatic Diseases
- Pancreatic Neoplasms
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 76 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03535727
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Dung Le, MD Johns Hopkins Medical Institution
Get Well Soon